Barclays Upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) to "Equal Weight"

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) was upgraded by equities research analysts at Barclays from an "underweight" rating to an "equal weight" rating in a report released on Tuesday, Benzinga reports. The firm presently has a $26.00 target price on the stock, up from their previous target price of $9.00. Barclays's target price would suggest a potential upside of 2.89% from the stock's previous close.

Several other equities research analysts have also recently weighed in on the company. Stifel Nicolaus upped their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research report on Wednesday, February 7th. Jefferies Financial Group reiterated a "hold" rating and set a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Wednesday, March 20th. Finally, Jonestrading reissued a "hold" rating and set a $25.60 price objective on shares of Deciphera Pharmaceuticals in a report on Monday. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $24.17.

Deciphera Pharmaceuticals Stock Down 0.0 %

Deciphera Pharmaceuticals stock traded down $0.01 during midday trading on Tuesday, reaching $25.27. The stock had a trading volume of 4,960,319 shares, compared to its average volume of 1,169,447. The firm's 50-day moving average price is $15.78 and its 200 day moving average price is $14.45. Deciphera Pharmaceuticals has a 12 month low of $9.90 and a 12 month high of $25.40. The firm has a market capitalization of $2.08 billion, a PE ratio of -11.06 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million for the quarter, compared to analysts' expectations of $45.93 million. During the same period in the prior year, the business posted ($0.60) earnings per share. The company's revenue was up 32.9% on a year-over-year basis. Equities research analysts expect that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Institutional Trading of Deciphera Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C boosted its stake in shares of Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company's stock valued at $87,738,000 after purchasing an additional 190,580 shares during the period. Armistice Capital LLC boosted its stake in shares of Deciphera Pharmaceuticals by 12.7% during the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock valued at $83,876,000 after purchasing an additional 588,000 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Deciphera Pharmaceuticals by 14.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company's stock valued at $37,220,000 after purchasing an additional 290,968 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Deciphera Pharmaceuticals by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company's stock valued at $25,191,000 after purchasing an additional 92,410 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its stake in shares of Deciphera Pharmaceuticals by 176.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company's stock valued at $16,482,000 after purchasing an additional 651,800 shares during the period. Hedge funds and other institutional investors own 70.96% of the company's stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.